H. Michael Shepard

Enosi Life Sciences Announces Executive Appointments as the Company Prepares for Period of Growth

Retrieved on: 
Thursday, April 29, 2021
H. Michael Shepard

Huitt\xe2\x80\x99s expertise as a contract executive includes leading finance, accounting, and operations while implementing corporate governance initiatives.

Key Points: 
  • Huitt\xe2\x80\x99s expertise as a contract executive includes leading finance, accounting, and operations while implementing corporate governance initiatives.
  • \xe2\x80\x9cEnosi\xe2\x80\x99s portfolio of immuno-oncology therapeutic candidates has vast potential to both provide more optimal treatment outcomes for patients and generate value for our shareholders.\xe2\x80\x9d\n\xe2\x80\x9cWe are pleased to add both Jeff and Thomas to Enosi Life Sciences as we prepare for a period of growth and enhanced shareholder visibility,\xe2\x80\x9d said Dr. H. Michael Shepard, co-founder of Enosi Life Sciences.
  • Enosi Life Sciences combines Feldmann and Shepard\xe2\x80\x99s expertise in cancer and autoimmune diseases with Executive Chairman Dr. James N. Woody\xe2\x80\x99s unique combination of medical, scientific and management expertise to expand therapeutic options.
  • To learn more about Enosi Life Sciences, visit www.enosi-life.com .\n'

Enosi Life Sciences Appoints Drug Discovery Veteran Patrick Gray as its Newest Board Member

Retrieved on: 
Tuesday, February 16, 2021
H. Michael Shepard, Life sciences, Biotechnology, Companies

SAN DIEGO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Enosi Life Sciences , a drug research and development company focused on providing industry-leading therapeutics for inflammatory autoimmune diseases and cancer, announced today its appointment of Patrick Gray, CEO of Pascal Biosciences , as its newest board member.

Key Points: 
  • SAN DIEGO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Enosi Life Sciences , a drug research and development company focused on providing industry-leading therapeutics for inflammatory autoimmune diseases and cancer, announced today its appointment of Patrick Gray, CEO of Pascal Biosciences , as its newest board member.
  • Dr. Grays demonstrated success as a discovery scientist and his experience within executive leadership is a perfect fit for our board, said Dr. H. Michael Shepard, co-founder of Enosi Life Sciences.
  • Enosi Life Sciences is a drug research and development company focused on providing industry-leading therapeutics for autoimmune diseases and cancer.
  • To learn more about Enosi Life Sciences, visit www.enosi-life.com .

Zymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the CD47 Blocker ALX148 in Patients with Advanced HER2‑Expressing Breast Cancer

Retrieved on: 
Monday, November 16, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Clinical medicine, Medicine, Cancer, Clusters of differentiation, Antineoplastic drugs, HER2/neu, CD47, Targeted therapy, Breast cancer, Trastuzumab emtansine, H. Michael Shepard, Zymeworks Inc., ALX Oncology

Our collaboration with ALX Oncology and their CD47 blocker, ALX148, has the potential to further expand the opportunity for zanidatamab to provide benefit to a broader population of patients, including those with advanced HER2expressing breast cancer.

Key Points: 
  • Our collaboration with ALX Oncology and their CD47 blocker, ALX148, has the potential to further expand the opportunity for zanidatamab to provide benefit to a broader population of patients, including those with advanced HER2expressing breast cancer.
  • Zanidatamab is designed to have multiple mechanisms of action, including immune clearance of HER2-expressing tumor cells by macrophages through antibody-dependent cellular phagocytosis (ADCP).
  • This collaboration builds on the promising anti-tumor activity observed in clinical trials of ALX148 combined with a HER2-targeted therapy in patients with advanced HER2-positive gastric and gastroesophageal cancer.
  • Zanidatamab is in advanced clinical development, actively enrolling a pivotal study in patients with previously-treated HER2 gene-amplified biliary tract cancer.

Therapeutic Antibody Pioneers Professor Sir Marc Feldmann and Dr. H. Michael Shepard Formally Launch Enosi Life Sciences

Retrieved on: 
Wednesday, September 2, 2020
Medical specialties, Medicine, Life sciences, Immunology, Biotechnology, Knights Bachelor, Marc Feldmann, H. Michael Shepard, TNF inhibitor

SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- World-renowned scientists Professor Sir Marc Feldmann and Dr. H. Michael Shepard are pleased to announce the formal launch of Enosi Life Sciences (Enosi), a company generating industry-leading scientific solutions to provide improved therapeutic approaches for autoimmune diseases and cancer.

Key Points: 
  • SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- World-renowned scientists Professor Sir Marc Feldmann and Dr. H. Michael Shepard are pleased to announce the formal launch of Enosi Life Sciences (Enosi), a company generating industry-leading scientific solutions to provide improved therapeutic approaches for autoimmune diseases and cancer.
  • Sir Feldmann helped develop Infliximab, the first anti-TNF therapeutic to show dramatic results for autoimmune diseases.
  • Enosi Life Sciences is a drug research and development company focused on providing industry-leading therapeutics for autoimmune diseases and cancer.
  • Enosi Life Sciences consolidates Feldmann and Shepards expertise in cancer and autoimmune diseases with a unique combination of medical, scientific and management expertise to expand therapeutic options from its executive team.

EXUMA Biotech Adds H. Michael Shepard to Scientific Advisory Board and Steven R. Frank to Board of Directors

Retrieved on: 
Tuesday, June 16, 2020
Medical specialties, Immunology, Genentech, Medicine, RTT, Trastuzumab, H. Michael Shepard, Health, Exuma

Additionally, Steven R. Frank has been named to the company's Board of Directors effective April 2020.

Key Points: 
  • Additionally, Steven R. Frank has been named to the company's Board of Directors effective April 2020.
  • H. Michael Shepard, Ph.D. is known for leading the research team that discovered the antibody therapy Herceptin (trastuzumab).
  • "I speak for the entire EXUMA Biotech team in expressing our enthusiasm in welcoming a long-time colleague and scientific trailblazer to our Scientific Advisory Board.
  • EXUMA Biotech Corp. is a private Delaware corporation formed in November 2015 with operations in West Palm Beach, Florida, the Cayman Islands and Shanghai, China.

Xencor to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, May 26, 2020
Biotechnology, Pharmaceutical, Health, Oncology, Life sciences, Medical specialties, Biology, Immunology, Biotechnology, Immune system, Monoclonal antibody, Antibody, Biopharmaceutical, Anogen, H. Michael Shepard

A replay will be posted on the Xencor website approximately one hour after the live event and will be available for 30 days.

Key Points: 
  • A replay will be posted on the Xencor website approximately one hour after the live event and will be available for 30 days.
  • Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases.
  • Currently, 17 candidates engineered with Xencor's XmAb technology are in clinical development internally and with partners.
  • Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action.

Aprea Therapeutics to Present at 2020 RBC Capital Markets Global Healthcare Conference

Retrieved on: 
Monday, May 18, 2020
Branches of biology, Tumor suppressor genes, Proteins, Carcinogenesis, Tumor suppressor, P53, H. Michael Shepard

BOSTON, May 18, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc.(Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that Christian S. Schade, President and Chief Executive Officer, and Eyal C. Attar, Senior Vice President and Chief Medical Officer, will participate in a fireside discussion at the 2020 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2020 at 11:30 a.m.

Key Points: 
  • BOSTON, May 18, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc.(Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that Christian S. Schade, President and Chief Executive Officer, and Eyal C. Attar, Senior Vice President and Chief Medical Officer, will participate in a fireside discussion at the 2020 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2020 at 11:30 a.m.
  • Aprea Therapeutics, Inc.is a biopharmaceutical company headquartered inBoston, Massachusettswith research facilities inStockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivatemutant tumor suppressor protein, p53.
  • The Companys lead product candidate is APR-246 (eprenetapopt), a small molecule in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
  • Corporate Contacts: Scott M. Coiante Sr. Vice President and Chief Financial Officer 617-463-9385 Gregory A. Korbel Vice President of Business Development 617-463-9385

Aprea Therapeutics Launches New Corporate Website - www.aprea.com

Retrieved on: 
Monday, April 6, 2020
Branches of biology, Cancer, Tumor suppressor genes, Proteins, Transcription factors, Apoptosis, Programmed cell death, Tumor suppressor, P53, Acute myeloid leukemia, Cyclacel, H. Michael Shepard

BOSTON, April 06, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc.(Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, today announced that it has launched a new, redesigned website, www.aprea.com .

Key Points: 
  • BOSTON, April 06, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc.(Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, today announced that it has launched a new, redesigned website, www.aprea.com .
  • Aprea Therapeutics, Inc.is a biopharmaceutical company headquartered inBoston, Massachusettswith research facilities inStockholm, Sweden, focused on developing and commercializing novel cancer therapeutics to reactivatemutant tumor suppressor protein, p53.
  • The Companys lead product candidate is APR-246 (eprenetapopt), a small molecule in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
  • The p53 tumor suppressor gene is the most frequently mutated gene in human cancer, occurring in approximately 50% of all human tumors.

Triumvira Immunologics and Lonza Announce Collaboration to Develop Innovative Point-of-Care Manufacturing for TAC T-Cell Therapeutic Targeting Solid Tumors

Retrieved on: 
Tuesday, March 24, 2020
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Medicine, Clinical medicine, Cancer, Cancer treatments, Antineoplastic drugs, HER2/neu, Genentech, Oncology, H. Michael Shepard, Tumor antigen vaccine, Triumvira Immunologics, Lonza

This collaboration, aimed at the development of Triumvira's TAC01-HER2 T-cell therapy for treating solid tumors, will leverage Lonza's expertise in process development and the usage of its proprietary Cocoon Platform.

Key Points: 
  • This collaboration, aimed at the development of Triumvira's TAC01-HER2 T-cell therapy for treating solid tumors, will leverage Lonza's expertise in process development and the usage of its proprietary Cocoon Platform.
  • Immunotherapy, particularly T-cell products, belong to the most potent drugs that could overcome the complex barriers encountered in solid tumors.
  • The TAC receptor represents a significant advancement, providing a novel mechanism of T-cell activation, leading to improved anti-tumor responses in solid tumor models.
  • Within this collaboration, TAC01-HER2 will initially be tested in a Phase 1/2 clinical trial examining different HER2-overexpressing solid tumors.

Xencor to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, February 6, 2020
Biotechnology, Pharmaceutical, Health, Oncology, Life sciences, Medical specialties, Biology, Immunology, Biotechnology, Immune system, Monoclonal antibodies, Antibody, Biopharmaceutical, Anogen, H. Michael Shepard

A replay of the events will be posted on the Xencor website approximately one hour after the live events and will be available for 30 days following the presentations.

Key Points: 
  • A replay of the events will be posted on the Xencor website approximately one hour after the live events and will be available for 30 days following the presentations.
  • Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases.
  • Currently, 15 candidates engineered with Xencor's XmAb technology are in clinical development internally and with partners.
  • Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action.